Hyloris Pharmaceuticals SA

As of December 31, 2025, Hyloris Pharmaceuticals SA carries a market capitalization of 191.52M, placing it among publicly traded companies globally. Its enterprise value stands at 179.36M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hyloris Pharmaceuticals SA's next confirmed earnings release is scheduled for March 17, 2027.

As of December 31, 2025, Hyloris Pharmaceuticals SA has 28.00M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Hyloris Pharmaceuticals SA maintains a current ratio of 3.89, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 19, 2026, Hyloris Pharmaceuticals SA's stock has declined approximately 29.05% over the past 52 weeks. The 50-day moving average sits at 4.70, while the 200-day moving average is 5.81.

As of December 31, 2025, Hyloris Pharmaceuticals SA holds 13.78M in cash and equivalents against 1.61M in total debt, resulting in a net debt position of -13.77M. Total book value stands at 26.48M, with working capital of 14.83M providing operational flexibility.